Table 1 Clinical and molecular features... | American Society of Hematology

Table 1

Clinical and molecular features with respect to LEF1 expression in B-precursor ALL (overall cohort)

Characteristic	LEF1 low (n = 211)	LEF1 high (n = 71)	P
Age, y			.39
Median	37	39
Range	15-64	16-65
Sex, %			.34
Male	50	56
WBC, × 10^9/L*			.58
Median	15	14
Range	0.8-594	0.5-581
> 30 × 10⁹/L, %	37	38	.89
CNS involvement, no. (%)			1.0
Yes/total	8/156 (5)	2/52 (4)
Molecular genetics
BCR-ABL⁺, no. (%)	82 (39)	35 (49)	.13
MLL-AF4⁺, no. (%)	21 (10)	2 (3)	.08
BAALC, high %†	54	39	.54
CD34⁺, %	76	75	.87
CD20⁺, %	30	48	.009
Myeloid markers, %‡	48	27	.001
Immunophenotypic subtype, no. (%)			.20§
Common ALL	138 (66)	45 (63)
Pre-B ALL	45 (21)	21 (30)
Pro-B ALL	28 (13)	5 (7)
GMALL risk groups, %‖			.25§
Standard-risk	70/210 (33)	21/70 (30)	.77
High-risk	59/210 (28)	14/70 (20)	.43
Very high-risk	82/210 (39)	35/70 (50)	.33
Allogeneic SCT in CR1, %	37	36	1.0

Characteristic	LEF1 low (n = 211)	LEF1 high (n = 71)	P
Age, y			.39
Median	37	39
Range	15-64	16-65
Sex, %			.34
Male	50	56
WBC, × 10^9/L*			.58
Median	15	14
Range	0.8-594	0.5-581
> 30 × 10⁹/L, %	37	38	.89
CNS involvement, no. (%)			1.0
Yes/total	8/156 (5)	2/52 (4)
Molecular genetics
BCR-ABL⁺, no. (%)	82 (39)	35 (49)	.13
MLL-AF4⁺, no. (%)	21 (10)	2 (3)	.08
BAALC, high %†	54	39	.54
CD34⁺, %	76	75	.87
CD20⁺, %	30	48	.009
Myeloid markers, %‡	48	27	.001
Immunophenotypic subtype, no. (%)			.20§
Common ALL	138 (66)	45 (63)
Pre-B ALL	45 (21)	21 (30)
Pro-B ALL	28 (13)	5 (7)
GMALL risk groups, %‖			.25§
Standard-risk	70/210 (33)	21/70 (30)	.77
High-risk	59/210 (28)	14/70 (20)	.43
Very high-risk	82/210 (39)	35/70 (50)	.33
Allogeneic SCT in CR1, %	37	36	1.0

CNS indicates central nervous system.

N = 268.

Above median expression level.

Coexpression of CD13, CD33, CD65s, or CD15.

Overall P value for the frequency of the 3 immunophenotypes/risk groups across the LEF1 expression groups.

N = 280.